Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer
Introduction Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states s...
| 發表在: | Archives of Medical Science |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Termedia Publishing House
2020-04-01
|
| 主題: | |
| 在線閱讀: | https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.html |
| _version_ | 1850282881389166592 |
|---|---|
| author | Magdalena Niedolistek Marta M. Fudalej Aleksandra Sobiborowicz Anna Liszcz Michał P. Budzik Maciej Sobieraj Janusz Patera Aleksandra Czerw Urszula Religioni Maria Sobol Andrzej Deptała Anna M. Badowska-Kozakiewicz |
| author_facet | Magdalena Niedolistek Marta M. Fudalej Aleksandra Sobiborowicz Anna Liszcz Michał P. Budzik Maciej Sobieraj Janusz Patera Aleksandra Czerw Urszula Religioni Maria Sobol Andrzej Deptała Anna M. Badowska-Kozakiewicz |
| author_sort | Magdalena Niedolistek |
| collection | DOAJ |
| container_title | Archives of Medical Science |
| description | Introduction
Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states such as cancers. The main purpose of our study was to evaluate the immunohistochemical expression of osteopontin in connection with the analysis of recognized clinical and pathological prognostic factors in primary sites of TNBC with and without lymph node metastases.
Material and methods
The immunohistochemical evaluation of osteopontin expression in 35 women with TNBC, chosen from a group of 726 patients, was performed. The material came from the excisional biopsies of primary breast cancers and total mastectomies.
Results
All patients showed expression of osteopontin, in most cases the expression of osteopontin rated at [+] (57.1%) and [++] (42.9%). Our study analyzed the relationship between the expression of osteopontin and traditional prognostic markers, such as the tumor grade, size, and lymph node involvement. We found a strong relationship only between the expression of osteopontin and the presence of lymph node metastases (p ≤ 0.0001). 93% of patients for whom the expression of osteopontin was determined at [++] had metastasis to lymph nodes and, for comparison, only 15% of women for whom the expression of osteopontin was rated at [+] showed the presence of metastases in the lymphatic nodes.
Conclusions
There is a correlation between osteopontin expression and the presence of lymph node metastases in TNBC, suggesting that osteopontin plays an important role in the invasiveness of TNBC. |
| format | Article |
| id | doaj-art-e6f8aebc8d514f2db4953665e82ee295 |
| institution | Directory of Open Access Journals |
| issn | 1734-1922 1896-9151 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| spelling | doaj-art-e6f8aebc8d514f2db4953665e82ee2952025-08-19T23:38:27ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512020-04-0120243644310.5114/aoms.2020.93695114841Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancerMagdalena Niedolistek0Marta M. Fudalej1Aleksandra Sobiborowicz2Anna Liszcz3Michał P. Budzik4Maciej Sobieraj5Janusz Patera6Aleksandra Czerw7Urszula Religioni8Maria Sobol9Andrzej Deptała10Anna M. Badowska-Kozakiewicz11Students’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandStudents’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Pathomorphology, Military Institute of Health Services, Warsaw, PolandDepartment of Health Economics and Medical Law, Medical University of Warsaw, Warsaw, PolandCollegium of Business Administration, Warsaw School of Economics, Warsaw, PolandDepartment of Biophysics and Human Physiology, Medical University of Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandDepartment of Cancer Prevention, Medical University of Warsaw, Warsaw, PolandIntroduction Triple-negative breast cancer (TNBC) is associated with lack of expression of estrogen and progesterone receptors and HER2 and is the subgroup of breast cancers with the worst prognosis. Osteopontin is a phosphorylated glycoprotein whose overexpression may occur in pathological states such as cancers. The main purpose of our study was to evaluate the immunohistochemical expression of osteopontin in connection with the analysis of recognized clinical and pathological prognostic factors in primary sites of TNBC with and without lymph node metastases. Material and methods The immunohistochemical evaluation of osteopontin expression in 35 women with TNBC, chosen from a group of 726 patients, was performed. The material came from the excisional biopsies of primary breast cancers and total mastectomies. Results All patients showed expression of osteopontin, in most cases the expression of osteopontin rated at [+] (57.1%) and [++] (42.9%). Our study analyzed the relationship between the expression of osteopontin and traditional prognostic markers, such as the tumor grade, size, and lymph node involvement. We found a strong relationship only between the expression of osteopontin and the presence of lymph node metastases (p ≤ 0.0001). 93% of patients for whom the expression of osteopontin was determined at [++] had metastasis to lymph nodes and, for comparison, only 15% of women for whom the expression of osteopontin was rated at [+] showed the presence of metastases in the lymphatic nodes. Conclusions There is a correlation between osteopontin expression and the presence of lymph node metastases in TNBC, suggesting that osteopontin plays an important role in the invasiveness of TNBC.https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.htmlimmunohistochemistryosteopontintriple-negative breast cancer |
| spellingShingle | Magdalena Niedolistek Marta M. Fudalej Aleksandra Sobiborowicz Anna Liszcz Michał P. Budzik Maciej Sobieraj Janusz Patera Aleksandra Czerw Urszula Religioni Maria Sobol Andrzej Deptała Anna M. Badowska-Kozakiewicz Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer immunohistochemistry osteopontin triple-negative breast cancer |
| title | Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer |
| title_full | Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer |
| title_fullStr | Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer |
| title_full_unstemmed | Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer |
| title_short | Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer |
| title_sort | immunohistochemical evaluation of osteopontin expression in triple negative breast cancer |
| topic | immunohistochemistry osteopontin triple-negative breast cancer |
| url | https://www.archivesofmedicalscience.com/Immunohistochemical-evaluation-of-osteopontin-expression-in-triple-negative-breast,114841,0,2.html |
| work_keys_str_mv | AT magdalenaniedolistek immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT martamfudalej immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT aleksandrasobiborowicz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT annaliszcz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT michałpbudzik immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT maciejsobieraj immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT januszpatera immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT aleksandraczerw immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT urszulareligioni immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT mariasobol immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT andrzejdeptała immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer AT annambadowskakozakiewicz immunohistochemicalevaluationofosteopontinexpressionintriplenegativebreastcancer |
